Individual drugs from two classes of glucoselowering agents, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodiumglucose cotransporter-2 inhibitors (SGLT2is), have demonstrated improved CV outcomes in high CV-risk subjects with T2D. This is reflected in recently updated guidelines from several professional associations -but not in the National Institute for Health and Care Excellence (NICE) guidelines in the UK. 2 We believe that NICE and other national/international health authorities need the ability to respond rapidly to new data, particularly when there is potential to improve outcomes and save lives.
Eight CV outcome trials (CVOTs) have already reported 1 and more are due to report as soon as this year, including CANVAS with canagliflozin, an SGLT2i (clinicaltrials.gov). aspirations appear to have emerged; a committee has met, and the update will be published in December 2017. However, previously, NICE has been reluctant to consider unlicensed indications, data published after their review process has started and, critically, to make any changes based on single studies; to satisfy the improved timescale for change, NICE may need to consider breaking these self-imposed rules.
To conclude, when trials demonstrate the potential for therapies to significantly improve clinical practice and patient outcomes, health advisory bodies have a duty of care, not only to be thorough and astute, but to fast-track their processes for consideration of the clinical implications of potentially important new data on managing patients at considerable risk of death or severe disability. Health authorities need to be able to review such data rapidly to consider whether such patients might benefit from the CV protection that these potentially major medical breakthroughs might offer.
The risk of cCardiovascular (CV) disease remains the biggest cause of morbidity and mortality higher in patients with type 2 diabetes (T2D) than in those without the disease. requires urgent revisiting particularly with regard to the 1.8mg dose, given the evidence from LEADER in 2016 that liraglutide has shown CV benefit, including reduced mortality.
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Additionally, the 'continuation' rules for GLP-1RAs appear paradoxical, requiring both a minimum drop in glycated haemoglobin (HbA 1c ) and weight loss, without evidence that the benefits are restricted to these circumstances. 9 The guidelines also currently adopt a 'waiting for failure' approach after the first intensification step, only recommending intensification when HbA 1c is 7·5% or higher. This is not an appropriate target for many patients, particularly those that are younger and more recently diagnosed with T2D.
When NICE published NG28 in 2015, it stated that areas 'that have not been reviewed may be addressed in 2 years' and iNICEt would consider a standing update committee for diabetes, which would enable a more rapid update, as and when new and relevant evidence iwasis published. 212 These aspirations appear to have emerged; a committee has met, and the update will be published in December 2017. However, this will be over two years after EMPA-REG OUTCOME was published, and 11 months after empagliflozin's EU licence update. Additionally, to satisfy this timescale for change, NICE will need to break self-imposed rules. However, pPreviously, NICE has been reluctant to consider unlicensed indications, data published after their review process has started and, critically, to make anymake any changes based on single studies; to satisfy the improvedis timescale for change, NICE will may need to consider breaking these self-imposed rules..
Since these CVOTs are all single studies, this could mean that all of these compelling data are ignored. Additionally, CANVAS will only be published after the NICE reviewing process has started, liraglutide awaits a licence update following LEADER and semaglutide is currently unlicensed. The CV outcome differences between GLP-1RAs would require NICE (and other national and international guidelines, many of which may be awaiting the decisions of NICE) to recommend individual drugs, rather than making recommendations on drug class.
To conclude, when trials demonstrate the potential for therapies to significantly improve clinical practice and patient outcomes, (such as reductions in major adverse CV events, including mortality beyond 30%), health authorities advisory bodies have a duty of care, not only to be thorough and astute, but to fast-track their processes for consideration of the clinical implications of potentially important new data on management ofmanaging patients at considerable risk of death or severe disability. Health authorities need to be able to review such data rapidly to consider whether such patients might benefit from the CV protection that these potentially major medical breakthroughs might offer.
